New York, USA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Peripheral T-Cell Lymphoma Market to Observe Growth at a CAGR of 4.9% in the US by 2032 | DelveInsight  The rapid growth in the peripheral T-cell lymphoma market is mainly attributed to the launch of ADCETRIS, along with the robust clinical pipeline and the expected launch of emerging therapies such as Azacitidine (CC-486), COPIKTRA (Duvelisib), etc.

纽约，美国，2023年11月21日（GLOBE NEWSWIRE）-外周T细胞淋巴瘤市场观察到到到2032年美国CAGR增长4.9%| DelveInsight外周T细胞淋巴瘤市场的快速增长主要归因于ADCETRIS的推出，以及强大的临床线道和预期推出的新兴疗法，如阿扎胞苷（CC-486），COPIKTRA（Duvelisib），等。

in the forecasted period (2023–2032). DelveInsight’s Peripheral T-Cell Lymphoma Market Insights report includes a comprehensive understanding of current treatment practices, peripheral T-cell lymphoma emerging drugs, market share of individual therapies, and current and forecasted peripheral T-cell lymphoma market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

在预测期间（2023年至2032年）。DelveInsight的外周T细胞淋巴瘤市场见解报告包括对当前治疗方法，外周T细胞淋巴瘤新兴药物，个体疗法的市场份额以及2019年至2032年当前和预测的外周T细胞淋巴瘤市场规模的全面了解，分为7MM[美国，EU-4（意大利，西班牙，法国和德国），英国和日本]。

Key Takeaways from the Peripheral T-Cell Lymphoma Market Report As per DelveInsight’s analysis, the peripheral T-cell lymphoma market size was found to be USD 564 million in 2021 in the 7MM and it is anticipated to grow at a significant CAGR by 2032.According to DelveInsight’s analysis, the total incident population of PTCL in the 7MM was approximately 18K in 2022, which is expected to grow during the study period, i.e., 2019–2032. Leading peripheral T-cell lymphoma companies such as Viracta Therapeutics, Dizal Pharmaceuticals, CStone Pharmaceuticals, Rhizen Pharmaceuticals, Myeloid Therapeutics, Secura Bio, Kura Oncology, BeiGene, Celgene Corporation, BMS, Affimed, Innate Pharma, Otsuka Pharmaceutical, Astex Pharmaceuticals, Merck Sharp & Dohme Corp., and others are developing novel peripheral T-cell lymphoma drugs that can be available in the peripheral T-cell lymphoma market in the coming years.Some of the key therapies fo.

外周T细胞淋巴瘤市场报告的主要收获根据DelveInsight的分析，到2021年，外周T细胞淋巴瘤市场规模在7MM中发现为5.64亿美元，预计到2032年将以显着的CAGR增长。根据DelveInsight的分析，到2022年，7MM中PTCL的总事件人口约为18K，主要的外周T细胞淋巴瘤公司，如Viracta Therapeutics，Dizal Pharmaceuticals，CStone Pharmaceuticals，Rhizen Pharmaceuticals，Myeloid Therapeutics，Secura Bio，Kura Oncology，BeiGene，Celgene Corporation，BMS，Affimed，Innate Pharma，Otsuka Pharmaceutical，Astex Pharmaceuticals，Merck Sharp＆Dohme Corp。，其他人正在开发新的外周T细胞淋巴瘤药物，这些药物可在未来几年的外周T细胞淋巴瘤市场中获得。一些关键疗法。